Deregulated Protein Kinases: Friend and Foe in Ischemic Stroke

Appunni, Sandeep; Gupta, Deepika; Rubens, Muni; Ramamoorthy, Venkataraghavan; Singh, Himanshu Narayan; Swarup, Vishnu

doi:10.1007/s12035-021-02563-y

Cited by 12 publications

(1 citation statement)

References 129 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The ELISA results showed that HSYA administration reduced the IL-1β levels. PRKCA, known as PKC-α, is a member of the PKC family of serine/threonine kinases [13]. Hang Yu et al [14] reported that angiopoietin-1 intervention reduces the loss function of the blood-brain barrier in rats with cerebral ischemia, and also downregulates PKC-α expression, indicating that reduced PKC-α expression contributes to improving cerebral ischemic events.…”

Section: Discussionmentioning

confidence: 99%

Network Analysis and Experimental Verification of the Mechanisms of Hydroxysafflor Yellow A in Ischemic Stroke Following Atherosclerosis

Han,

Zhou,

Yin

et al. 2023

Molecules

View full text Add to dashboard Cite

Hydroxysafflor yellow A (HSYA) is derived from Carthamus tinctorius L. (Honghua in Chinese) and is used to treat cardiovascular and cerebrovascular disease. However, the mechanism by which HSYA treats ischemic stroke following atherosclerosis (ISFA) remains unclear. The targets and pathways of HSYA against ISFA were obtained using network analysis. A total of 3335 potential IFSA-related targets were predicted using the GenCards and Drugbank databases, and a total of 88 potential HSYA-related targets were predicted using the Swiss Target Prediction database. A total of 62 HSYA-related targets against IFSA were obtained. The network was composed of HSYA, 62 targets, and 20 pathways. The top 20 targets were constructed via the protein–protein interaction (PPI) network. Gene Ontology analysis revealed that the targets were involved in signal transduction, protein phosphorylation, the cytoplasm, the plasma membrane, the cytosol, zinc ion binding, ATP binding, protein kinase binding/activity, and enzyme binding. The Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis revealed that the pathways were associated with cancer, inflammatory mediator regulation of the transient receptor potential channels, and microRNA in cancer. Additionally, molecular docking indicated that HSYA mainly interacts with five targets, namely interleukin 1 beta (IL-1β), signal transducer and activator of transcription 3 (STAT3), E1A-binding protein p300 (EP300), protein kinase C alpha (PRKCA), and inhibitor of nuclear factor kappa B kinase subunit beta (IKBKB). In animal experiments, HSYA administration ameliorated the infarct size, neurological deficit score, histopathological changes, carotid intima-media thickness (IMT), and blood lipid level (total cholesterol and triglycerides). Immunochemistry and quantitative PCR showed that HSYA intervention downregulated the expression of STAT3, EP300, PRKCA, and IKBKB, and the enzyme-linked immunoassay showed reduced IL-1β levels. The findings of this study provide a reference for the development of anti-ISFA drugs.

show abstract

Section: Discussionmentioning

confidence: 99%